
HIMS Stock Forecast & Price Target
HIMS Analyst Ratings
Bulls say
Hims & Hers Health is poised for long-term growth due to its convenient and personalized healthcare offerings, as well as its partnership with Novo Nordisk. While the company has faced some challenges, such as a recent earnings miss and competition in the market, their focus on expanding into new market segments and addressing legal concerns sets them up for potential success in the future. With a strong subscriber base and a solid business model, Hims & Hers has the potential to be a strong player in the telehealth industry.
Bears say
Hims & Hers Health is a telehealth platform with a negative outlook due to its declining average monthly revenue per subscriber, increasing competition from both established healthcare giants and nimble, venture-backed startups, and potential risks to its compounding business from tighter regulations. While the company has more than 2 million subscribers and is expanding globally, it faces challenges in maintaining durable unit economics and high marketing yields to sustain its DTC business model. Furthermore, its entrance into the GLP-1 market poses considerable risks due to heightened scrutiny from drug companies and potential regulatory challenges. While management remains bullish on the company's growth potential and has raised revenue guidance for fiscal year 2026, there are concerns about profitability and sustainability in the highly competitive telehealth industry.
This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.
HIMS Analyst Forecast & Price Prediction
Start investing in HIMS
Order type
Buy in
Order amount
Est. shares
0 shares